Evaxion appoints Dr Helen Tayton-Martin as new Chief Executive Officer
Dr Tayton-Martin brings broad experience of biotech company building, fund-raising, M&A, business development and operations with a strong track record...
Vaccine
Cocrystal Pharma Receives NIH SBIR Award to Advance its Influenza Inhibitor Program
BOTHELL, Wash., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces it has...
Cocrystal Pharma Receives NIH SBIR Award to Advance its Influenza Inhibitor Program
BOTHELL, Wash., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces it has...
Cocrystal Pharma Receives NIH SBIR Award to Advance its Influenza Inhibitor Program
BOTHELL, Wash., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces it has...
BioNTech to Report Third Quarter 2025 Financial Results and Corporate Update on November 3, 2025
MAINZ, Germany, October 27, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial...
BioNTech to Report Third Quarter 2025 Financial Results and Corporate Update on November 3, 2025
MAINZ, Germany, October 27, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial...
BioNTech to Report Third Quarter 2025 Financial Results and Corporate Update on November 3, 2025
MAINZ, Germany, October 27, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial...
CSL Honoured as Overall Winner of the 2025 Facility of the Year Awards by the International Society for Pharmaceutical Engineering (ISPE)
Setting new standards in responsible innovation, CSL's Broadmeadows facility blends Pharma 4.0™ principles with sustainable design to transform plasma manufacturing...
Data presented at ACR Convergence 2025 highlight Sobi’s commitment to advancing care across rare and underserved inflammatory conditions
NASP data highlight reduction in disease burden among people living with uncontrolled gout Gamifant (emapalumab) data showed response rates in...
Press release: Q3: continued sales and earnings progress
Q3: continued sales and earnings progress Paris, October 24, 2025 Q3 sales growth of 7.0% at CER1 and business earnings...
Award-Winning Film An Inconvenient Study Sparks Global Debate on Vaccine Safety and Chronic Disease
Following its viral global premiere, ICAN and Del Bigtree release a response to media criticisms of the unpublished vaccinated-versus-unvaccinated study...
Moderna Named a Top Employer by Science for Eleventh Consecutive Year
CAMBRIDGE, MA / ACCESS Newswire / October 23, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked as a...
Pumpkin Pet Insurance Now Part of the PetDesk Pet Insurance Guide for Smarter, Connected Pet Care
NEW YORK, Oct. 23, 2025 /PRNewswire/ -- Pumpkin Pet Insurance, one of the nation's fastest-growing pet insurance and wellness brands,...
Anixa Biosciences to Present at the Spartan Capital Securities Second Annual Investor Conference
SAN JOSE, Calif., Oct. 23, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company...
Moderna to Host Investor Event – Analyst Day
CAMBRIDGE, MA / ACCESS Newswire / October 23, 2025 / Moderna, Inc. (Nasdaq:MRNA) today announced that it will host its...
Moderna Announces Phase 3 Study of Investigational Cytomegalovirus (CMV) Vaccine Did Not Meet Primary Efficacy Endpoint
Company to discontinue development of mRNA-1647 in congenital CMVCompany will continue to evaluate mRNA-1647 in ongoing Phase 2 trial in...
In Treating Measles Infection, NV-387 Showed Strong Antiviral Activity, and Significantly, Protected Lungs from Damage, Describes NanoViricides
SHELTON, CONNECTICUT / ACCESS Newswire / October 22, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer:NNVC) (the "Company"),...
Medicus Pharma Ltd. Announces First Patient Treated in United Arab Emirates (UAE) Sknjct-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin
CLEVELAND CLINIC ABU DHABI (CCAD) IS THE PRINCIPAL INVESTIGATOR IN THIS 36 PARTICIPANT STUDY PHILADELPHIA, PA / ACCESS Newswire /...
WORK Medical Technology Group LTD Announces US$1 Million Equity Investment in Neologics Bioscience
Hangzhou, China, Oct. 21, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical” or the “Company”),...
Consortium consisting of Nordic Capital and Permira lowers the minimum acceptance condition to 66 2/3% in respect of the takeover offer to the shareholders of Bavarian Nordic
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE...